华润三九与博瑞医药就BGM0504注射液项目 签订合作研发协议

Group 1 - The core viewpoint of the news is the collaboration between China Resources Sanjiu (华润三九) and Borui Pharmaceutical (博瑞医药) to develop the BGM0504 injection, aimed at addressing the rising public health challenges of Type 2 Diabetes Mellitus (T2DM) and obesity in China [1][2] - The BGM0504 injection is a dual agonist of GLP-1 and GIP receptors, classified as an innovative peptide drug, and is currently in the critical phase of Phase III clinical trials [2] - The partnership aims to leverage the strengths of both companies, combining China Resources Sanjiu's commercial capabilities with Borui Pharmaceutical's research advantages to accelerate the development and commercialization of BGM0504 in the Chinese market [2] Group 2 - The collaboration is expected to enhance the brand's competitive edge by focusing on weight loss and blood sugar reduction, while also exploring other potential indications for the drug [2] - Both companies emphasize the importance of addressing unmet clinical needs and aim to efficiently translate innovative results into clinical value for patients [2] - The cooperative model of resource sharing and complementary advantages is anticipated to lead to mutual benefits for both companies and ultimately benefit patients [2]